NEW YORK (GenomeWeb) – Ncardia said today that it has entered into a non-exclusive global intellectual property licensing agreement with Evotec, which gives Evotec access to patented technology and methods for stem cell-derived modeling for target discovery, drug efficacy, and safety testing.

Ncardia has developed a variety of predictive human cellular assays systems, including a broad panel of induced pluripotent stem cell (iPSC)-derived lines of both cardiac cells and neurons.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.